Global Organs-on-Chips Market- Growth, Trends and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 708602
出版日期 內容資訊 英文 109 Pages
商品交期: 2-3個工作天內
生物功能晶片的全球市場:成長率,趨勢及預測分析(2019年∼2024年) Global Organs-on-Chips Market- Growth, Trends and Forecast (2018 - 2023)
出版日期: 2019年02月01日內容資訊: 英文 109 Pages




第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 動物實驗的替代方案的必要條件
    • 藥物毒性的早期發現的必要性
    • 新產品的銷售及技術的進步
  • 市場阻礙因素
    • 生物功能晶片模式的複雜性
  • 產業的魅力:波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭的激烈程度

第5章 市場區隔

  • 內臟器官類型
    • 肝臟
    • 心臟
    • 其他的內臟器官類型
  • 各應用領域
    • 藥物研發
    • 毒物學研究
    • 其他的用途
  • 各終端用戶
    • 製藥及生物科技企業
    • 學術研究機關
    • 其他的終端用戶
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他各國(ROW)

第6章 競爭情形

  • 企業簡介
    • AxoSim Inc.
    • BiomimX SRL
    • Elveflow
    • Emulate Inc.
    • Hurel Corporation
    • InSphero AG
    • Nortis Inc.
    • Tara Biosystems
    • TissUse GmbH

第7章 市場機會及未來趨勢


Product Code: 64233

Market Overview

An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and air flow in organs, such as lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional 2D and 3D culture systems. It offers a wide range of applications, such as diseases modeling, patient stratification, and phenotypic screening.

The organ-on-chip market is driven by factors, such as a requirement for alternatives for animal testing, need for early detection of drug toxicity, and new product launches and advancements in technology that are also responsible for driving the market. Furthermore, the surging initiatives by pharmaceutical companies, to invest and investigate drug repurposing utilizing organs-on-chips models, are also expected to drive the growth of the organs-on-chip market.

The demand for personalized medication and the vast applications of organ-on-chip beyond the pharmaceutical industry are the major factors creating growth opportunities for market players.

There are also increasing product launches by several key players, intended to expand their product portfolio, which are further expected to increase their market in the upcoming forecast years.

The market studied is greatly influenced by the launches of new products by the major market players, which is further expected to increase their market shares in the coming years. For instance, in March 2017, InSphero AG launched the 3D InSight Monkey Liver Microtissues, which resulted in the expansion of the company's suite of organotypic 3D liver models for in vitro safety and efficacy testing.

Scope of the Report

An organ-on-chip (OOC) is also called as multi-channel 3D microfluidic cell culture chip. It is a type of artificial organ that simulates activities, mechanics, and physiological responses of entire organs and organ systems. The size of the OOC is about an AA battery, and its transparency allows to see the organ's functionality, behavior, and response at the cellular and molecular levels.

Key Market Trends

Drug Discovery Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period

The drug discovery segment of the organ-on-chip market is expected to hold the largest market share, and is projected to witness a CAGR of 34.72% during the forecast period.

The pharmaceutical industry is facing many challenges due to the rising cost and declining efficiency of drug R&D. Thus, there is a critical need for new testing approaches for generating reliable predictions of drug efficacy. OOC has the potential to serve as a new enabling platform for the identification and validation of efficacy, safety, and durability of potential targets early in the pipeline, thus ncreasing the chances of success in clinical trials.

Eventually, OOC models may play a pivotal role in streamlining the clinical trial processes. For instance, advances in stem cell engineering could be integrated into the OOC technology to develop personalized models to predict patient-specific toxicity and efficacy, which could lead to more efficient human trials with significantly reduced preclinical testing requirements. The OOC technology can be mutually integrated with modeling and analysis tools in the drug discovery process. Furthermore, the OOC models could be used to validate potential targets identified by genomics and proteomics analyses. These developments have the potential to transform the process of drug discovery and development in the future, which may contribute directly to the growth of the market.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America currently dominates the OOC market owing to factors, such as the availability of a wide range of services offered by major players (which includes customized designing of new chips with specific organ arrangement) and increase in toxicological testing of chemicals on the different types of organ cells. Huge investments are being made by the public and private institutes for their research. For instance, the Wyss Institute received almost USD 5.6 million in grant money from the US FDA to use its organ-on-chip technology to test human physiological responses to radiation and to evaluate drugs designed to counter those effects.

Competitive Landscape

The organ-on-chip market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as AxoSim Inc., BiomimX SRL, Elveflow, Emulate Inc., Hurel Corporation, InSphero AG, MIMETAS BV, Nortis Inc., Tara Biosystems, and TissUse GmbH, is, in turn, increasing the overall competitive rivalry in the market. Product advancements and improvements in the organ-on-chip platforms by the major players are increasing the competitive rivalry.

Major Players

AxoSim Inc.

BiomimX SRL


Emulate Inc.

Hurel Corporation

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Requirement of Alternative for Animal Testing
    • 4.2.2 Need for Early Detection of Drug Toxicity
    • 4.2.3 New Products Launches and Advancements in Technology
  • 4.3 Market Restraints
    • 4.3.1 Complexity of Organ-on-chip Models
  • 4.4 Industry Attractiveness Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Organ Type
    • 5.1.1 Liver
    • 5.1.2 Heart
    • 5.1.3 Lung
    • 5.1.4 Other Organ Types
  • 5.2 By Application
    • 5.2.1 Drug Discovery
    • 5.2.2 Toxicology Research
    • 5.2.3 Other Applications
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Academic and Research Institutes
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Rest of the World (ROW)


  • 6.1 Company Profiles
    • 6.1.1 AxoSim Inc.
    • 6.1.2 BiomimX SRL
    • 6.1.3 Elveflow
    • 6.1.4 Emulate Inc.
    • 6.1.5 Hurel Corporation
    • 6.1.6 InSphero AG
    • 6.1.7 MIMETAS BV
    • 6.1.8 Nortis Inc.
    • 6.1.9 Tara Biosystems
    • 6.1.10 TissUse GmbH

List Not Exhaustive